News

FDA recall medical device recall product recall

Thousands of heart surgery kits recalled due to FDA quality concerns

Specific lots of several procedure kits have been recalled after the FDA identified quality issues during a recent inspection.

Performing transcatheter aortic valve replacement (TAVR) with the J-Valve transcatheter heart valve (THV) may help limit the risk of coronary artery obstruction (CAO) in high-risk patients, according to a new study published in Clinical Interventions in Aging.[1]

TAVR with Edwards Lifesciences valve for severe AR linked to ‘encouraging’ data

All patients presented with severe aortic regurgitation. The study's findings were presented at New York Valves 2026 and published in JSCAI.

Investigational heart drug for nonobstructive HCM one step closer to FDA approval

No drugs are currently approved by the FDA for the treatment of symptomatic, nonobstructive HCM. Could oral therapy ninerafaxstat be the first?

passport visa foreign international travel

Radiologists say visa-processing delays could pose potential patient care crisis

ACR and other medical societies recently wrote to the secretaries of State and Homeland Security to voice their concern about ongoing staffing issues.

Targeted interventions could help reduce pre-test anxiety, improve the physical screening experience, and address structural barriers in underserved settings.

CMS projection: 90% of Americans will still have health insurance in 2034—when healthcare spending reaches $9T

Legislative changes, demographic shifts and growing demand will combine to drive national health spending to almost $9 trillion by 2034.

In 3-game healthcare series, underdog large-language models sweep specialized AI powerhouses

Pitting three multipurpose LLMs against two healthcare-specific AI tools, researchers have discovered the consumer-level AI can beat its purpose-built counterparts in healthcare scenarios—and soundly, at that.

Kaiser Permanente to pay community hospital over $82M to resolve out-of-network reimbursement dispute

The lawsuit dates back to 2019 but has been stuck in the court process for years. In the end, the health plan will pay Pomona Valley Hospital for emergency care delivered to patients at an out-of-network rate—though the facility didn’t get all of what it was seeking.

OIG warns of ‘ghost network’ trouble in maternal health managed care

Looking at the three largest Medicaid managed care plans related to maternal health, the Office of Inspector General found instances of ineligible providers being included in directories, as well as other errors such as incorrect contact information.

The A-FLUX Reducer System from VahatiCor is designed to treat coronary microvascular dysfunction.

First US patient enrolled in device study to reduce coronary microvascular dysfunction

The self-expanding A-Flux device is implanted in the coronary sinus to increase pressure on the venous side of the heart and improve perfusion in smaller vessels.

Rad tech society establishes scholarships in memory of 2 influential members

The two imaging pros played a significant role in advancing medical imaging and radiation therapy, according to the ASRT.

Breast cancer AI ribbon pink artificial intelligence

FDA clears RadNet's AI-powered breast arterial calcification solution

In clinical testing, the module achieved 90% sensitivity and 88% specificity across patients with varying levels of breast density.

Around the web

Cardiovascular Business

Thousands of heart surgery kits recalled due to FDA quality concerns

Specific lots of several procedure kits have been recalled after the FDA identified quality issues during a recent inspection.

Cardiovascular Business

TAVR with Edwards Lifesciences valve for severe AR linked to ‘encouraging’ data

All patients presented with severe aortic regurgitation. The study's findings were presented at New York Valves 2026 and published in JSCAI.

Cardiovascular Business

Investigational heart drug for nonobstructive HCM one step closer to FDA approval

No drugs are currently approved by the FDA for the treatment of symptomatic, nonobstructive HCM. Could oral therapy ninerafaxstat be the first?